Advanced Solid Tumours Clinical Trial
Official title:
A Cancer Research UK Phase I Study to Determine the Maximum Tolerated Dose of the Oral Src/Abl Inhibitor AZD0424, and to Identify Tolerable and Effective AZD0424 Combination Regimens for the Treatment of Advanced Solid Tumours
The purpose of this study is to determine the maximum tolerated dose of the oral Src/Abl inhibitor AZD0424, and to find tolerable and effective AZD0424 combination regimens for the treatment of advanced solid tumours
AZD0424 is a potent orally available, potent (IC50 approximately 4 nM) inhibitor of Src and
ABL1 kinases with additional activity against Src family kinase (SFK) members including Yes
and Lck. AZD0424 was selective for SFKs and ABL1 kinase over C-terminal Src kinase (a
negative regulator of Src) and a range of other kinase targets. The anti-cancer activity of
AZD0424 is thought to be mediated primarily by anti-migratory and anti-invasive signalling
and, as such, it is expected that in the late stage cancer setting strong signals of efficacy
with this compound used as a single agent are unlikely, requiring it to be administered in
combination with other anti-cancer agents.
In summary the study will be performed in four main stages:
- AZD0424 monotherapy, dose escalation: Phase Ia single agent (AZD0424) dose escalation
study to determine the MTD.
- AZD0424 monotherapy, dose expansion: Phase Ib single agent dose expansion at MTD (up to
six additional patients may be recruited in order to provide paired tumour biopsies for
PD analysis).
- Combination arm dose escalation: Provided that it is deemed appropriate (after review of
available clinical data from the monotherapy part of the trial, and available
preclinical and published data on the combination), a Phase Ia dose escalation arm of
AZD0424 in combination with the selected agent will proceed to determine the MTD for the
combination and a recommended Phase II dose.
- Combination arm dose expansion: Phase Ib combination arm using the recommended Phase II
dose for both AZD0424 and the combination agent.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05514132 -
A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours
|
Phase 1 | |
Terminated |
NCT04949425 -
A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours
|
Phase 1 | |
Not yet recruiting |
NCT05537051 -
A Study of PM1021 (Anti-TIGIT) With or Without PM8001 (Anti-PD-L1/TGF-β) in Patients With Advanced Solid Tumours
|
Phase 1 | |
Completed |
NCT02579226 -
A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors.
|
Phase 1 | |
Completed |
NCT01058538 -
A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid Tumours
|
Phase 1/Phase 2 | |
Completed |
NCT02588105 -
Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer
|
Phase 1 | |
Recruiting |
NCT03852823 -
Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours
|
Phase 1 | |
Not yet recruiting |
NCT06380816 -
A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01585701 -
Phase I Study of AT13148, a Novel AGC Kinase Inhibitor
|
Phase 1 | |
Completed |
NCT03101839 -
Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours
|
Phase 1 | |
Completed |
NCT03150368 -
Extended Use of ModraDoc006/r
|
Phase 1 | |
Active, not recruiting |
NCT02389842 -
PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib
|
Phase 1 | |
Terminated |
NCT01581060 -
Phase I/II Dose-escalation Study to Investigate Safety and Pharmacokinetics/ Pharmacodynamics of WX-554 in Patients With Solid Tumours
|
Phase 1/Phase 2 | |
Terminated |
NCT04959266 -
A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib
|
Phase 1 | |
Completed |
NCT04462952 -
Study of Adavosertib(AZD1775) in Japanese Patients With Advanced Solid Tumours
|
Phase 1 | |
Active, not recruiting |
NCT03518606 -
Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours
|
Phase 1/Phase 2 | |
Completed |
NCT02430311 -
The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour.
|
Phase 1 | |
Terminated |
NCT01859351 -
Phase I Study of WX-037 Alone and in Combination With WX-554 in Solid Tumours
|
Phase 1 | |
Completed |
NCT01163903 -
Pantoprazole With Doxorubicin for Advanced Cancer Patients With Extension Cohort of Patients With Solid Tumours
|
Phase 1 | |
Recruiting |
NCT05804526 -
A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours
|
Phase 1/Phase 2 |